Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Retatrutide is a triple incretin receptor agonist (GLP-1, GIP, and glucagon) under Phase 3 clinical development by Eli Lilly
The Key Takeaways: Most common: Nausea (43%), manageable with dietary changes and timing Unique: Dysesthesia (20.9%), mild tingling sensations, not seen with Wegovy/Mounjaro Timeline: Worst during dose escalation (weeks 116), significant improvement after Discontinuation: 18.2% in TRIUMPH-4, 11.3% in TRIUMPH-1 the general obesity population tolerates it better than the osteoarthritis cohort Reversible: Stopping medication reverses side effects For most people with obesity especially severe obesity the 28.328.7% weight loss and associated health benefits outweigh the temporary discomfort during the first few months
Recommendations for Use General use level: 0.1%1%
When stored outside recommended temperature ranges specified in FDA labeling, these medications may experience reduced efficacy, potentially leading to suboptimal glycemic control or inadequate weight management
Improves skin health from the inside out
If you take L-Carnitine and remain sedentary, the transported fats will not be burned and will simply be stored again
US$ 25.14
US$ 25.38
US$ 26.62
US$ 21.37
US$ 28.21
US$ 29.19
US$ 24.24
US$ 24.02
US$ 28.62
US$ 22.50
US$ 28.45
